Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SELP | P16109 | 5/20 | 0.42 |
| ▸ | SELE | P16581 | 5/20 | 0.42 |
| ▸ | SELL | P14151 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15681755 | 0.76 | THRB (0.44) | GAAKMT2AHPGDPOLBLMNA | |
| SCHEMBL16610341 | 0.76 | MLYCD (0.51) | GAAKMT2AHPGDPOLBMAPT | |
| SCHEMBL18273964 | 0.75 | ERCC1 (0.57) | GAAKMT2AHPGDMAPTMEN1 | |
| SCHEMBL30791530 | 0.74 | HPGD (0.55) | KMT2AHPGDMEN1 | |
| SCHEMBL8606890 | 0.71 | GAA (0.66) | GAAKMT2AMAPTMEN1LMNA | |
| SCHEMBL28012614 | 0.71 | TRPV1 (0.52) | HPGDPOLBSMN1; SMN2 | |
| SCHEMBL16610336 | 0.71 | TRPV1 (0.52) | HPGDPOLBSMN1; SMN2 | |
| SCHEMBL29056178 | 0.70 | GAA (0.68) | GAAKMT2AMAPTMEN1LMNA | |
| SCHEMBL7245988 | 0.70 | GAA (0.64) | GAAKMT2AMAPTMEN1LMNA | |
| SCHEMBL8781731 | 0.69 | HPGD (0.49) | GAAKMT2AHPGDMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409664-B1 | APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS | TASLY PHARMACEUTICAL GROUP CO (CN) | 2021-01-06 | — | — | EP | claimed |
| US-20190046500-A1 | APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATION | TASLY PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-14 | — | — | US | claimed |
| EP-3409664-A1 | APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS | Tasly Pharmaceutical Group Co., Ltd. (CN) | 2018-12-05 | — | — | EP | claimed |
| CN-104513172-A | Trifluoromethyl-containing amide alkaloids, and preparation method and drug use thereof | TASLY PHARMACEUTICAL GROUP CO | 2015-04-15 | — | — | CN | claimed |
| EP-3409664-B1 | APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS | TASLY PHARMACEUTICAL GROUP CO (CN) | 2021-01-06 | — | — | EP | disclosed |
| EP-3409664-B1 | APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS | TASLY PHARMACEUTICAL GROUP CO (CN) | 2021-01-06 | — | — | EP | disclosed |
| US-10874636-B2 | Application of substituted cinnamamide derivatives in preparation of anti-anxiety medication | TASLY PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-10874636-B2 | Application of substituted cinnamamide derivatives in preparation of anti-anxiety medication | TASLY PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-20190046500-A1 | APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATION | TASLY PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
| US-20190046500-A1 | APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATION | TASLY PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
| EP-3409664-A1 | APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS | Tasly Pharmaceutical Group Co., Ltd. (CN) | 2018-12-05 | — | — | EP | disclosed |
| CN-104513172-A | Trifluoromethyl-containing amide alkaloids, and preparation method and drug use thereof | TASLY PHARMACEUTICAL GROUP CO | 2015-04-15 | — | — | CN | disclosed |
| WO-2015043522-A1 | TRIFLUOROMETHYL-CONTAINING AMIDE ALKALOID, MANUFACTURING METHOD AND PHARMACEUTICAL USE THEREOF | 天士力制药集团股份有限公司 | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874636-B2 | Application of substituted cinnamamide derivatives in preparation of anti-anxiety medication | CBR3, CYP4F3, CYP4F2 | GAA 3368/4885KMT2A 1181/4885HPGD 2268/4885 |
| US-20190046500-A1 | APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATION | CBR3, CYP4F3, CYP4F2 | GAA 3368/4885KMT2A 1181/4885HPGD 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.